Sensex, Nifty End Choppy Session Marginally Higher

(RTTNews) - Indian shares recovered from an early slide to end marginally higher on Wednesday as the dollar pulled back slightly and U.S. Treasury yields retreated after rising in the previous session.

The dollar eased slightly after rising on Tuesday as June U.S. CPI data showed early signs of tariff-linked inflation.

Oil prices also traded lower in European trade as tariff-related worries overshadowed expectations of firm summer demand in the world's two largest consumers, the United States and China.

After striking a trade deal with Indonesia, U.S. President Donald Trump announced potential tariffs on imported pharmaceuticals by month's end, followed by semiconductor levies.

Trump also said that a trade agreement with Vietnam was nearly complete and that the United States is close to getting full trade access to India.

India is taking a "wait and watch approach" with a senior government official telling PTI that the government will decide how to respond to the upcoming U.S. tariffs only after fully understanding their impact.

The benchmark S&P/BSE Sensex ended a choppy session up 63.57 points, or 0.08 percent, at 82,634.48, while the broader NSE Nifty index closed at 25,212.05, up 16.25 points, or 0.06 percent, from its previous close.

The BSE mid-cap and small-cap indexes edged up by 0.1 percent and 0.3 percent, respectively.

The market breadth was strong on the BSE, with 2,339 shares rising while 1,719 shares declined and 160 shares closed unchanged.

Infosys, SBI, Tech Mahindra and Mahindra & Mahindra all rose around 2 percent while Tata Steel, Sun Pharma and Eternal dropped 1-2 percent.

HDB Financial Services lost 3.1 percent on reporting a marginal decline in its first-quarter net profit.

Just Dial plunged 5 percent despite reporting 13 percent growth in quarterly profit. Dixon Technologies added 1.8 percent after it agreed to acquire a 51 percent stake in Kunshan Q Tech Microelectronics.

Biocon gained 1.1 percent as the U.S. drug regulator approved its key diabetes treatment drug.